SCHEMBL5301508

SCHEMBL5301508

NC(=O)N(c1ccccc1)c1ccc(-c2cccc3onc(N)c23)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 16/20 0.62
KIT P10721 15/20 0.62
FLT3 P36888 11/20 0.62
MET P08581 4/20 0.52
SRC P12931 2/20 0.51
PLK4 O00444 1/20 0.51
ROCK2 O75116 1/20 0.51
RPS6KA5 O75582 1/20 0.51
MAP4K4 O95819 1/20 0.51
RET P07949 1/20 0.51
PDGFRB P09619 1/20 0.51
PIM1 P11309 1/20 0.51
FGFR1 P11362 1/20 0.51
PDGFRA P16234 1/20 0.51
PRKACA P17612 1/20 0.51
RPS6KB1 P23443 1/20 0.51
LTK P29376 1/20 0.51
GRK5 P34947 1/20 0.51
MAP2K2 P36507 1/20 0.51
FRK P42685 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13372660 0.91 KDR (0.67) KDRKITFLT3METSRC
SCHEMBL5306431 0.91 KDR (0.59) KDRKITFLT3METSRC
SCHEMBL5306131 0.91 KIT (0.67) KDRKITFLT3METSRC
SCHEMBL27636362 0.90 KDR (0.58) KDRKITFLT3METSRC
SCHEMBL27636423 0.89 KDR (0.60) KDRKITFLT3METSRC
SCHEMBL28757596 0.89 KDR (0.60) KDRKITFLT3METSRC
SCHEMBL422409 0.89 KDR (0.61) KDRKITFLT3METSRC
SCHEMBL6800761 0.89 KDR (0.60) KDRKITFLT3METSRC
SCHEMBL27657349 0.88 KIT (0.69) KDRKITFLT3MET
SCHEMBL5308026 0.88 KDR (0.62) KDRKITFLT3METSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1850839-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON INC. (CH) 2007-11-07 EP claimed
WO-2006091801-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON, INC. (CH) 2006-08-31 WO claimed
CN-1826324-A Indazole, benzisoxazole and benzisothiazole kinase inhibitors ABBOTT LAB (US) 2006-08-30 CN claimed
CN-101827584-A Solid dispersion product of N-aryl ureido drugs ABBOTT GMBH & CO KG 2010-09-08 CN disclosed
CN-1826324-A Indazole, benzisoxazole and benzisothiazole kinase inhibitors ABBOTT LAB (US) 2006-08-30 CN disclosed